Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jia Shen Tablets for Chronic Heart Failure with Coronary Heart Disease
NCT06669169Phase 2Not yet recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Jiashen Tablets in chronic heart failure (CHF) and coronary heart disease (CHD) (3 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: 6-Minutes-Walking-Distance at 12 weeks. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
Jiashen Tablets
03
Conditions
chronic heart failure (CHF)coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT06669169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669169.